Rocket Pharmaceuticals Inc (RCKT) Stock Price, Quote & News

Company Profile

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases in the United States. It develops vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inher...

Industry: Biotechnology

Sector: Healthcare

Phone: 609 659 8001

Website: www.rocketpharma.com

Address:

9 Cedarbrook Drive, Cranbury, United States

mailman1961 Sep. 16 at 4:58 PM

$RCKT looks like a seller at 3.29. Every attempt since early September to get past 3.30 has been met with a seller. Last time it was over 3.30 was September 5. I think if it can break that, we could get some upside noise.

0 · Reply

Chickenforyou Sep. 16 at 4:13 PM

$RCKT big ups rn, why?

1 · Reply

mailman1961 Sep. 15 at 10:08 PM

$RCKT let's hope the sharp reversal off a red biotech day marks the end of the bleeding here. Some strange price action today.

1 · Reply

MoneyGroupLLC Sep. 13 at 6:36 PM

Enter: $RCKT OCT 17 2025 $5 CALLS Buy in Price: $0.07 - $0.10 Take Profit: $0.09 Stop Bleeding: $0.06 ROI Potential: 33% Exit Within: 54 Minutes https://moneygroup.us/alerts

0 · Reply

Orlandotrader Sep. 12 at 7:28 PM

$RCKT Holding 50 day at 3.14. We move below and we head towards 2.75. There I Add to my 1000 from 3.50.

0 · Reply

SirBank Sep. 11 at 5:23 PM

$RCKT

0 · Reply

AStrokeOfLuck Sep. 11 at 4:18 PM

$RCKT

0 · Reply

DinoMcnuggets Sep. 10 at 6:04 PM

$RCKT BofA increased price target from 21$ to 24$ today following conference updates.

1 · Reply

Stephanovich7654568 Sep. 9 at 11:27 PM

$RCKT From 2017 to 2018, shares went from $4 to $24. In 12 month only. Be patient. Your luck will come. Bigger than in your little dream. ❤️

1 · Reply

Stephanovich7654568 Sep. 9 at 11:23 PM

$RCKT They did these two conference to attract investors. Once they did attracted them, someone will like buy for 30 millions dollars worth of new shares that they will emit. The share will stay at the same price for a while and once they filled up their buying shares, the shares will go down a little and then they will explode. They should go pretty high. The management seem to woke up. The cleaned the slate and slab. This company never went for split shares since the day they were born and that to me is a great sign of respect for the share holder. The shares will pop up on time and maybe higher than you could imagine. Not worried at all. Sleep tight. 🌛❤️

0 · Reply

Rocket Pharmaceuticals, Inc. (RCKT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Aug 28, 2025, 7:00 AM EDT - 19 days ago

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

Aug 20, 2025, 11:02 AM EDT - 27 days ago

Gene Therapy Trial Can Restart After Patient Death, FDA Says. The Sector Remains Depressed.

Aug 20, 2025, 9:31 AM EDT - 27 days ago

FDA Lifts Rocket Pharmaceuticals Study Hold For Rare Disease Gene Therapy

Aug 20, 2025, 7:09 AM EDT - 27 days ago

US FDA lifts clinical hold on Rocket Pharmaceuticals' gene therapy trial

Aug 20, 2025, 7:00 AM EDT - 27 days ago

Rocket Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on the Pivotal Phase 2 Trial of RP-A501 for the Treatment of Danon Disease

Aug 8, 2025, 2:16 PM EDT - 5 weeks ago

DEADLINE NEXT WEEK: Berger Montague Advises Rocket Pharmaceuticals (NASDAQ: RCKT) Investors to Contact the Firm Before August 11, 2025

Aug 7, 2025, 4:00 PM EDT - 5 weeks ago

Rocket Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Progress

Jul 30, 2025, 6:29 PM EDT - 6 weeks ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals

Jul 30, 2025, 11:07 AM EDT - 6 weeks ago

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

CAPR SRPT CABA NGNE NTLA QURE

Jul 29, 2025, 10:26 AM EDT - 7 weeks ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals

Jul 25, 2025, 3:02 PM EDT - 7 weeks ago

Rocket Refocuses Pipeline As Gene Therapy Sentiment Sours

Jul 24, 2025, 4:02 PM EDT - 7 weeks ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of August 11, 2025 in Rocket Pharmaceuticals, Inc. Lawsuit – RCKT

Jul 24, 2025, 7:00 AM EDT - 7 weeks ago

Rocket Pharmaceuticals Announces Strategic Corporate Reorganization and Pipeline Prioritization of Cardiovascular Programs

Jul 17, 2025, 7:00 AM EDT - 2 months ago

Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A601 Gene Therapy for PKP2-Arrhythmogenic Cardiomyopathy

Jul 11, 2025, 10:25 AM EDT - 2 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals

Jul 9, 2025, 5:16 PM EDT - 2 months ago

Berger Montague PC Investigates Rocket Pharmaceuticals (RCKT) Over Safety Disclosures and Stock Drop

Jul 7, 2025, 9:00 AM EDT - 2 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of August 11, 2025 in Rocket Lawsuit - RCKT

Jun 30, 2025, 7:00 AM EDT - 2 months ago

Rocket Pharmaceuticals Announces FDA IND Clearance of RP-A701 for the Treatment of BAG3-associated Dilated Cardiomyopathy

Jun 12, 2025, 10:00 AM EDT - 3 months ago

Rocket Pharmaceuticals, Inc. (RCKT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Jun 11, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Rocket Pharmaceuticals, Inc. (RCKT) Shareholders to Inquire about Securities Investigation

Jun 10, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Rocket Pharmaceuticals, Inc. (RCKT) And Encourages Shareholders to Connect

mailman1961 Sep. 16 at 4:58 PM

0 · Reply

Chickenforyou Sep. 16 at 4:13 PM

$RCKT big ups rn, why?

1 · Reply

mailman1961 Sep. 15 at 10:08 PM

$RCKT let's hope the sharp reversal off a red biotech day marks the end of the bleeding here. Some strange price action today.

1 · Reply

MoneyGroupLLC Sep. 13 at 6:36 PM

Enter: $RCKT OCT 17 2025 $5 CALLS Buy in Price: $0.07 - $0.10 Take Profit: $0.09 Stop Bleeding: $0.06 ROI Potential: 33% Exit Within: 54 Minutes https://moneygroup.us/alerts

0 · Reply

Orlandotrader Sep. 12 at 7:28 PM

$RCKT Holding 50 day at 3.14. We move below and we head towards 2.75. There I Add to my 1000 from 3.50.

0 · Reply

SirBank Sep. 11 at 5:23 PM

$RCKT

0 · Reply

AStrokeOfLuck Sep. 11 at 4:18 PM

$RCKT

0 · Reply

DinoMcnuggets Sep. 10 at 6:04 PM

$RCKT BofA increased price target from 21$ to 24$ today following conference updates.

1 · Reply

Stephanovich7654568 Sep. 9 at 11:27 PM

$RCKT From 2017 to 2018, shares went from $4 to $24. In 12 month only. Be patient. Your luck will come. Bigger than in your little dream. ❤️

1 · Reply

Stephanovich7654568 Sep. 9 at 11:23 PM

0 · Reply

pjapak Sep. 9 at 7:17 PM

$RCKT CEO need to buy shares. What is he waiting for when everything is on track?

2 · Reply

AStrokeOfLuck Sep. 9 at 4:09 PM

$RCKT Hmmm, still no traction yet with 2 recent conferences. Probably wouldn't hurt to get a Kresladi update/timeline.

1 · Reply

Dickky Sep. 9 at 1:54 PM

$RCKT wakeee wakeee baby

0 · Reply

Stephanovich7654568 Sep. 8 at 2:10 AM

$RCKT Omnes una prosperemus. RCKT iterum resurget.

0 · Reply

Newtimmy Sep. 7 at 11:37 AM

$RCKT Looking

0 · Reply

ali93277 Sep. 6 at 1:06 AM

$RCKT Morgan Stanley 23rd Annual Global Healthcare Conference 📍 New York 📅 September 9, 2025 🕘 9:15 AM ET 💬 Management will present updates and meet with institutional

0 · Reply

Stephanovich7654568 Sep. 5 at 10:56 PM

$RCKT When I was young Apple was not a gem. It grew. You have to give time. Check the red bars and the green bars. There are more green then red. But you will say that the price is not moving. We have been stable for a while now. It means that someone is buying a million dollar worth of shares per day with his #1 wallet and is selling back to is #2 wallet to keep the price around low $3 per share. It really looks like a buyout is coming if everything goes ok. I invested $5000 dollars in FNMA when the war started. Two years later I sold at $6.20 and I made $62,000 dollars. Now they are worth over $12 dollars. I got lucky. If you are patient, you will get rewarded. Go outs ou tside and play. Just forget about it for a while. ❤️ Bullish

0 · Reply

flashmem Sep. 5 at 2:27 PM

$RCKT Sold and took the loss here from 3.60. Just an awful trade for me. May revisit later but this trades like trash for now.

0 · Reply

pjapak Sep. 5 at 2:09 PM

$RCKT Rationally world need gene therapy more than AI. But it's crazy world 🤯

1 · Reply

AStrokeOfLuck Sep. 4 at 5:21 PM

$RCKT 2026 not that far away....

0 · Reply

StockConsultant Sep. 4 at 11:52 AM

$RCKT Rocket Pharmaceuticals stock watch, pullback to 3.16 support with bullish indicators, target 4.5 area at https://stockconsultant.com/?RCKT

0 · Reply

xXCronoSXx Sep. 3 at 9:05 PM

$RCKT Cantor takeaways: ✅ Danon de-risked: CEO explained the C3 issue; pivot to ~4×10¹³ vg/kg, no C3 inhibitor, earlier C5—aligned with Ph1 safety/efficacy. ⚠️ Timeline: Next 3 patients targeted early 2026; bigger data later. ❓ KRESLADI: No new CMC/refile update. Verdict: Good for the long-term thesis; not a near-term re-rating. #GeneTherapy #biotech

2 · Reply

Market Cap	340.98M
Revenue (ttm)	0.00
Net Income (ttm)	-258.75M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	880,457
Avg Vol	4,014,976
Day's Range	N/A - N/A
Shares Out	107.90M
Stochastic %K	42%
Beta	0.62
Analysts	Sell
Price Target	$8.60